Regional cohort for patients with irritable bowel syndrome
Official title: Development of a Regional Irritable Bowel Syndrome Cohort
Run by University Hospital, Rouen · NCT06900491 · Data updated 2026-11-12
This study is trying to learn more about irritable bowel syndrome by following around 600 patients for 2.5 years to see how the condition affects them and how it can be treated better.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 600 (estimated) |
| Sponsor | University Hospital, Rouen Academic / other |
| Locations | 4 sites (Amiens and 3 other locations) |
| Status | Recruiting |
| Started | March 4, 2025 |
| Main results expected | September 4, 2030 |
| Study ends | September 4, 2030 |
| Registry record updated | January 8, 2026 |
| Trial ID | NCT06900491 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults over 18 years old who have been diagnosed with irritable bowel syndrome and have normal laboratory work-ups.
✕Probably not a fit
Patients with organic digestive pathologies or major digestive surgeries, as well as those who do not speak or understand French, may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This project aims to establish a multicentre, longitudinal cohort of individuals suffering from irritable bowel syndrome (IBS) to study the natural history and prognosis of the disease. The study will involve comprehensive phenotyping of patients through questionnaires, physiological explorations, and stool sample analyses to assess microbiota and metabolites. Over a period of 2.5 years, the study plans to include approximately 600 patients, allowing for the identification of subgroups with similar clinical or biological characteristics. This approach will facilitate a better understanding of IBS and its treatment outcomes.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and management of irritable bowel syndrome, potentially enhancing patient outcomes.
How similar studies have gone: Other studies have successfully utilized similar cohort approaches to understand IBS, indicating that this methodology is both tested and promising.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient * Normal laboratory work-up as part of routine care (CBC, CRP) * Over 18 years of age * Patient affiliated to a social security scheme * Person who has read and understood the information letter and does not object to taking part in the study Exclusion Criteria: * Patient suffering from an organic digestive pathology (chronic inflammatory bowel disease, microscopic colitis when endoscopy has been performed because deemed necessary, digestive cancer, coeliac disease) or major digestive surgery (excluding appendectomy and cholecystectomy). * Patient refusal * Patient does not speak or understand French * A pregnant woman or a woman in labour or breastfeeding * Person deprived of liberty by an administrative or judicial decision or person placed under court protection / sub- guardianship or curatorship
Where it's running
-
University Rouen Hospital
Rouen, France Recruiting -
University Hospitol of Amiens
Amiens, France Not yet recruiting -
CHU de CAEN
Caen, France Not yet recruiting -
University Hospital of Lille
Lille, France Not yet recruiting
Study contacts
- Study coordinator: David DM MALLET, Director
- Email: david.mallet@chu-rouen.fr
- Phone: 02 32 88 82 65
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Liver Fat and Scarring in People Suspected of Non-Celiac Wheat Sensitivity
This study looks to see if people with non-celiac wheat sensitivity have liver fat or fibrosis and how this relates to IBS/FD and celiac disease.
-
Repeated transcranial magnetic stimulation to treat diarrhea-predominant irritable bowel syndrome
This study will test whether repeated transcranial magnetic stimulation (rTMS) can reduce diarrhea, abdominal pain, and improve quality of life in adults with IBS-D.
-
Brenipatide (LY3537031) for IBS with constipation
This trial will test whether brenipatide (LY3537031), given by a small under-the-skin injection, helps adults with IBS-C have less belly pain and more normal bowel movements compared with a placebo.
-
Brenipatide (LY3537031) treatment for adults with IBS‑D
This will test whether brenipatide (LY3537031) given under the skin helps adults with IBS‑D reduce belly pain and improve stool consistency compared with placebo.
-
Camlipixant for IBS-D and IBS-M: a test in adults
This study tests camlipixant versus placebo in adults with IBS with diarrhea or mixed IBS to see if it helps reduce symptoms and is safe.
-
Defining Objective Markers of Dietary Compliance in IBS
This study tests whether a biomarker in stool or urine can reflect how much certain carbohydrates you eat, helping manage IBS.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.